Hepatitis C Vaccine Phase I Clinical Trial Kicks Off in Korea | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Have Quicker and More Effective Approaches Arrived for Eradicating Hepatitis C?

Back to News Homepage
Next

FDA Grants Breakthrough Therapy Designation for Treatment of Chronic HCV

Hepatitis C Vaccine Phase I Clinical Trial Kicks Off in Korea

The Editors at Hepatitis Central
October 25, 2013

Print this page

Additional clinical studies to assess INO-8000/VGX-6150, a vaccine for Hepatitis C, will also take place in the U.S. beginning in 2014.

Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial

Inovio is partnering with VGX International, its affiliate, in Korea

BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients. Under a 2011 collaborative development agreement, Inovio’s affiliate, VGX International Inc. (KSE: 011000), is fully funding and conducting the study at multiple sites in Korea. Inovio is also planning to evaluate this hepatitis C (HCV) vaccine in additional clinical studies in the U.S. beginning in 2014.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “More effective antiviral drugs have changed the prognosis for patients with hepatitis C; however, treatment failures remain and combination with an immunotherapeutic approach could make the difference for many patients. In preclinical studies, Inovio’s HCV immunotherapy has shown to generate powerful T cell responses in the liver, which could be important in clearing HCV-infected liver cells. We have already shown in published clinical studies that our vaccines generate best-in-class T-cell responses. In this study, the effects of Inovio’s HCV immunotherapy will be directly tested in patients who have previously failed standard drug therapies. We look forward to entering the hepatitis C treatment arena, which is one of the fastest-developing markets in healthcare, with a projected value of $20 billion by the end of the decade.”

Continue reading this entire article:
http://online.wsj.com/article/PR-CO-20131021-901438.html

No Comments - be the first!
Share
Share
Previous

Have Quicker and More Effective Approaches Arrived for Eradicating Hepatitis C?

Back to News Homepage
Next

FDA Grants Breakthrough Therapy Designation for Treatment of Chronic HCV

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.